Regeneron proposes gene therapy re-dosing solutions at ASGCT 

Regeneron is taking on the AAV gene therapy re-dosing challenge with two antibody-based strategies designed to lower neutralizing antibody levels enough to enable repeat dosing. The company’s genetic medicine division has cleared the first hurdle, demonstrating that re-dosing is possible in non-human primates.

At the American Society for Gene and Cell Therapy (ASGCT) annual meeting on Friday, Nicholas Giovannone, senior principal scientist at Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), presented data showing that an anti-CD40 mAb and an anti-CD20 x CD3 bispecific antibody were each effective at suppressing neutralizing antibody generation after initial treatment with an AAV gene therapy...